NCT01301716

A Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors

A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 75 (actual)
• Sponsor: Genentech, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label, multicenter, Phase Ib dose-escalation study to assess the safety, tolerability, and pharmacokinetics of GDC-0980 administered with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin to patients with locally advanced or metastatic solid tumors.

Conditions

• Solid Cancers

Interventions

Type	Name	Description
DRUG	GDC-0980	Oral escalating dose
DRUG	bevacizumab	Intravenous repeating dose
DRUG	carboplatin	Intravenous repeating dose
DRUG	cisplatin	intravenous repeating dose
DRUG	paclitaxel	Intravenous repeating dose
DRUG	pemetrexed	intravenous repeating dose

Timeline

• Start date: 2011-09-01
• Primary completion: 2014-08-01
• Completion: 2014-08-01
• First posted: 2011-02-23
• Last updated: 2016-11-02

Locations

5 sites across 2 countries: United States, Spain